Short Interest in Tema Oncology ETF (NASDAQ:CANC) Rises By 50.0%

Tema Oncology ETF (NASDAQ:CANC) was the recipient of a large increase in short interest during the month of September. As of September 15th, there was short interest totalling 600 shares, an increase of 50.0% from the August 31st total of 400 shares. Based on an average daily trading volume, of 7,300 shares, the short-interest ratio is currently 0.1 days.

Tema Oncology ETF Stock Performance

NASDAQ:CANC traded up $0.07 on Friday, hitting $28.32. The stock had a trading volume of 3,667 shares, compared to its average volume of 7,562. The stock has a market cap of $47.58 million, a P/E ratio of 26.86 and a beta of 1.11. Tema Oncology ETF has a 1 year low of $21.26 and a 1 year high of $30.11. The firm’s fifty day simple moving average is $28.96 and its two-hundred day simple moving average is $27.84.

Institutional Investors Weigh In On Tema Oncology ETF

An institutional investor recently bought a new position in Tema Oncology ETF stock. Thrivent Financial for Lutherans acquired a new stake in Tema Oncology ETF (NASDAQ:CANC) in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm acquired 319,376 shares of the company’s stock, valued at approximately $8,616,000. Thrivent Financial for Lutherans owned about 19.01% of Tema Oncology ETF as of its most recent filing with the SEC.

Tema Oncology ETF Company Profile

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.